PCOS Renamed to PMOS: Medical Rationale and Recognition

Medical term Polycystic Ovary Syndrome (PCOS) has been officially renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS). The change, agreed upon through international consensus in 2026, aims to provide a more accurate clinical description for patients.

Experts have noted that the term PCOS has often caused confusion, as “polycystic” suggests patients must have ovarian cysts, whereas many do not exhibit this symptom. In reality, the condition is more complex, involving hormonal imbalances, metabolic issues, and insulin resistance.

Data indicates the name change to PMOS emphasises the systemic nature of the disorder, which affects not only reproductive organs but also long-term health risks such as type 2 diabetes and cardiovascular disease.

Doctors confirm PMOS is not a new disease but a reclassification of PCOS; previous PCOS diagnoses automatically fall under PMOS. This is purely a medical terminology update to reflect the latest scientific understanding of women’s metabolic health.

Despite the name change, the primary diagnostic method remains the Rotterdam Criteria. A diagnosis of PMOS requires meeting at least two of three indicators:

Common symptoms include significant weight gain and difficulty conceiving. Experts estimate around 70% of global PMOS cases remain undiagnosed due to low awareness of metabolic symptoms.

The term PCOS is expected to coexist with PMOS for several years during the transition period to ease adaptation for healthcare professionals and the public.

This medical terminology update is hoped to promote earlier detection and more comprehensive management, focusing not just on fertility but also holistic metabolic health management. (The Lancet Consensus 2026, NCBI StatPearls, Endocrine Society, The Guardian, Verywell Health/Z-10)